•   
  •   

Health & Fitness New breast cancer treatment cuts risk of recurrence in patients by 25%

01:05  21 september  2020
01:05  21 september  2020 Source:   dailymail.co.uk

How coronavirus has affected breast cancer diagnosis and treatment

  How coronavirus has affected breast cancer diagnosis and treatment All the breast cancer advice and reassurance you need.Many women have felt wary as well – some may not have followed up on their symptoms, feeling reluctant to overload their GP or worried about having to attend a hospital appointment because of the risk of catching coronavirus.

Patients with a common type of breast cancer have seen the risk of recurrence cut by a quarter following a new treatment , a study has shown. Over two years, the phase three monarchE study found a 25 per cent reduction in recurrence of cancer when the CDK 4/6 inhibitor abemaciclib was

Breast cancer can recur at the original site (called recurrence or local recurrence ), as well as return and spread to other parts of the body (called metastasis or New therapies are being studied in clinical trials. The results of these studies will decide whether these therapies will become part of standard care.

a woman looking at the camera: MailOnline logo © Provided by Daily Mail MailOnline logo

Patients with a common type of breast cancer have seen the risk of recurrence cut by a quarter following a new treatment, a study has shown.

During the global study, led by the Royal Marsden NHS Foundation Trust, 5,637 patients in 38 countries who had hormone receptor positive (HR+) early stage breast cancer and were a high risk of recurrence were chosen to take part.

Over two years, the phase three monarchE study found a 25 per cent reduction in recurrence of cancer when the CDK 4/6 inhibitor abemaciclib was added to the standard hormone therapy compared with hormone therapy alone.

One in five women unlikely to visit doctor with breast health concerns

  One in five women unlikely to visit doctor with breast health concerns One in five women under 45 would be unlikely to visit a doctor if they noticed any unusual changes to their breasts, according to research released to mark the start of Breast Cancer Awareness Month. Concerns about the coronavirus pandemic have caused women to deprioritise their breast health, according to the research from Estee Lauder Companies’ Breast Cancer Campaign. More than two in five women also said they would be less likely to share any concerns about their breast health with friends and family, than they would have been before the pandemic.

Risk factors, treatments and types of breast cancer recurrence from the expert breast specialists at the Johns Hopkins Breast Center in Baltimore, MD. The majority of individuals diagnosed with breast cancer will never experience recurrence of their disease. However, if it does happen, breast cancer

Experts found the new treatment cut could the risk of breast cancer returning by a quarter Credit: Getty Images - Getty. The study was conducted over two years and the experts found that there was a 25 per cent reduction in recurrence of cancer when abemaciclib was added to the standard

The study has now been described as 'one of the most promising breakthroughs for patients with this type of breast cancer in the last 20 years', according to the institution.

a woman sitting on a table: Patients who had hormone receptor positive (HR+) early stage breast cancer and were a high risk of recurrence saw a 25 per cent reduction in recurrence of cancer when the CDK 4/6 inhibitor abemaciclib was added to their treatment. (Stock image) © Provided by Daily Mail Patients who had hormone receptor positive (HR+) early stage breast cancer and were a high risk of recurrence saw a 25 per cent reduction in recurrence of cancer when the CDK 4/6 inhibitor abemaciclib was added to their treatment. (Stock image)

In their study, the institution tested if patients taking the CDK 4/6 inhibitor abemaciclib along with hormone therapy following standard of care treatments such as chemotherapy, surgery and/or radiotherapy were at a reduced risk of recurrence compared with the standard hormone treatment alone.

Is the UK on the Verge of a Cancer Crisis? This Oncologist and Professor Explains Why

  Is the UK on the Verge of a Cancer Crisis? This Oncologist and Professor Explains Why Provided a 'second wave' doesn't hit, Professor Karol Sikora believes the dissipation of coronavirus could lead to an implosion of cancer cases across the country and provide a killing blow to an-already weakened NHSOn March 23rd, a country-wide 'lockdown' was initiated by the UK, a move that saw wide-ranging restrictions on freedom of movement, enforced by law, prohibiting non-essential activities in a bid to help curb the already-rapid spread of the novel coronavirus (COVID-19). Gyms, barbers and non-essential shops closed to fight it. Public transport emptied. People followed the #StayHome rules and clapped for the NHS' unwavering resilience every Thursday.

decreased the risk of breast cancer recurrence by 25 % compared to standard adjuvant ET alone (HR The median duration on Verzenio was 14 months. No new safety signals were observed. rate of hospitalization for coronavirus patients using its antibody treatment Video at CNBC.com (Wed, 7

A regional breast cancer recurrence means the cancer has come back in the nearby lymph nodes. For people with breast cancer who have an increased risk of cancer recurrence , chemotherapy has been shown Ruddy KJ, et al. Approach to the patient following treatment for breast cancer . https

Some 11.3 per cent of patients in the control group suffered a relapse of their cancer compared with 7.8 per cent of those in the abemaciclib group, Royal Marsden said.

Around 70 per cent of breast cancer patients have hormone receptor positive tumours, and a proportion of those have a higher risk of relapse in the first two years, it added.

'Patients with disease that has spread to lymph nodes, a large tumour size at the time of diagnosis, or an increased cellular proliferation (determined by high grade of the tumour, or number of dividing cells) were considered to be at 'high risk' of recurrence and recruited to the study' Royal Marsden said.

Study patient Sarah Ryder, 57, from Dorset, said she 'did not feel much hope' after finding out her cancer had spread to 23 lymph nodes when she was referred last year.

She said: 'The trial has helped me believe in a future again. I can see my daughter grow up, go off to university next year and maybe have a family of her own one day.'

Breast cancer cells could one day be manipulated to help treat tumours

  Breast cancer cells could one day be manipulated to help treat tumours Breast cancer cells could one day be manipulated to actually treat tumours, research suggests. Scientists from John Hopkins University believe so-called natural killer (NK) immune cells can be turned from foe to friend in the fight against the disease. Read more:BBC presenter with 'incurable cancer' is free of the disease Breast cancer cells spread by invading surrounding healthy tissue until they reach the bloodstream, which enables them to form secondary tumours elsewhere.NK cells normally destroy malignant tissue. The scientists discovered, however, they can be reprogrammed by breast cancer cells to facilitate their spread.

If you have breast cancer , absolute risk also can be used to describe the likelihood of a certain treatment outcome or the course of the So in this scenario, what difference does radiation therapy really make for you in terms of reducing the absolute risk of cancer recurrence in the same breast ?

Recurrent breast cancer is cancer that has come back in the same or opposite breast or chest If you were already treated for breast cancer and now have a new diagnosis of recurrent breast Treatment for regional recurrence . If breast cancer comes back in the lymph nodes in the armpit or

Professor Stephen Johnston, consultant medical oncologist at the Royal Marsden and professor of breast cancer medicine at the Institute of Cancer Research, said: 'This research could potentially save many lives in the future.'

In their study, the institution tested if patients taking the CDK 4/6 inhibitor abemaciclib along with hormone therapy were at a reduced risk of recurrence. (Stock image) © Provided by Daily Mail In their study, the institution tested if patients taking the CDK 4/6 inhibitor abemaciclib along with hormone therapy were at a reduced risk of recurrence. (Stock image)

He added: 'The monarchE research has given us confidence that we will soon be able to offer our high risk HR+ patients a greater chance of keeping them cancer-free.

'While there have been many advances in other early breast cancer subtypes such as HER2 positive disease, there has been no significant advancements for the large group of patients who have hormone receptor positive breast cancer since the late 1990s when aromatase inhibitors were introduced.

The results of the monarchE study are being presented at the European Society for Medical Oncology Virtual Congress on Sunday evening and simultaneously published in the Journal of Clinical Oncology.

The monarchE trial was funded by Eli Lilly pharmaceutical.

Read more

Record 1.85m NHS patients now waiting 18+ weeks for hospital treatment .
Data released by NHS England showed that the number of people who have been waiting for more than a year for an operation or procedure is 50 times higher than it was in June 2019.Data from NHS England shows the number of people waiting more than 52 weeks to start hospital treatment in England also rose to 50,536. It is the biggest year-long waiting list since February 2009. By contrast, only 1,089 had been waiting 12 months for treatment last June.

—   Share news in the SOC. Networks
usr: 1
This is interesting!